52 results
8-K
EX-10.2
URGN
UroGen Pharma Ltd.
8 Aug 24
Departure of Directors or Certain Officers
4:30pm
) employee retention; (xlii) initiation of studies by specific dates; (xliii) budget management; (xliv) submission to, or approval by, a regulatory … ) progress of internal research or development programs; (xlvii) acquisition of new customers; (xlviii) customer retention and/or repeat order rate; (xlix
8-K
EX-1.1
URGN
UroGen Pharma Ltd.
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
the Securities Act, including timely filing with the Commission or retention where required and legending, and each such free writing prospectus, as of its issue
424B5
URGN
UroGen Pharma Ltd.
18 Jun 24
Prospectus supplement for primary offering
5:05pm
warmed to body temperature. We believe that these characteristics promote ease of delivery into and retention of drugs in body cavities, including
424B5
pdu0u
17 Jun 24
Prospectus supplement for primary offering
4:19pm
8-K
EX-99.1
ur95apgaqd8h5
13 Jun 24
Regulation FD Disclosure
10:51am
8-K
EX-99.3
ih79wm1kfdt
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am
8-K
EX-99.2
flk3y
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am